A study that attempts to address the resistance issue by using the first-ever MET inhibitor ‘Tabrecta’ in combination with the EGFR-TKI ‘Tagrisso,’ will be conducted in Korea.

According to the Ministry of Drug and Food Safety on the 25th, Novartis Korea’s application to conduct a Phase III trial on its non-small cell lung cancer treatment ‘Tabrecta (capmatinib)’ was approved that day. Tabrecta is the first-ever MET inhibitor to be approved by the U.S. FDA and was approved in June last year. In Korea, the drug has been designated as an orphan drug by the MFDS in the pre-approval stage.

The new clinical trial that will be conducted by Novartis will be studying Tabrecta in combinatio